Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination
(2013) In Journal of Experimental Medicine 210(3). p.563-579- Abstract
- Therapy-induced resistance remains a significant hurdle to achieve long-lasting responses and cures in cancer patients. We investigated the long-term consequences of genetically impaired angiogenesis by engineering multiple tumor models deprived of endoglin, a co-receptor for TGF-beta in endothelial cells actively engaged in angiogenesis. Tumors from endoglin-deficient mice adapted to the weakened angiogenic response, and refractoriness to diminished endoglin signaling was accompanied by increased metastatic capability. Mechanistic studies in multiple mouse models of cancer revealed that deficiency for endoglin resulted in a tumor vasculature that displayed hallmarks of endothelial-to-mesenchymal transition, a process of previously unknown... (More)
- Therapy-induced resistance remains a significant hurdle to achieve long-lasting responses and cures in cancer patients. We investigated the long-term consequences of genetically impaired angiogenesis by engineering multiple tumor models deprived of endoglin, a co-receptor for TGF-beta in endothelial cells actively engaged in angiogenesis. Tumors from endoglin-deficient mice adapted to the weakened angiogenic response, and refractoriness to diminished endoglin signaling was accompanied by increased metastatic capability. Mechanistic studies in multiple mouse models of cancer revealed that deficiency for endoglin resulted in a tumor vasculature that displayed hallmarks of endothelial-to-mesenchymal transition, a process of previously unknown significance in cancer biology, but shown by us to be associated with a reduced capacity of the vasculature to avert tumor cell intra- and extravasation. Nevertheless, tumors deprived of endoglin exhibited a delayed onset of resistance to anti-VEGF (vascular endothelial growth factor) agents, illustrating the therapeutic utility of combinatorial targeting of multiple angiogenic pathways for the treatment of cancer. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3651257
- author
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Experimental Medicine
- volume
- 210
- issue
- 3
- pages
- 563 - 579
- publisher
- Rockefeller University Press
- external identifiers
-
- wos:000315997000011
- scopus:84877629719
- pmid:23401487
- ISSN
- 1540-9538
- DOI
- 10.1084/jem.20120662
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Experimental oncology (013031110)
- id
- 77f3f3ba-bb91-41c5-a05e-134cae5ce63e (old id 3651257)
- date added to LUP
- 2016-04-01 14:50:26
- date last changed
- 2022-04-22 05:30:32
@article{77f3f3ba-bb91-41c5-a05e-134cae5ce63e, abstract = {{Therapy-induced resistance remains a significant hurdle to achieve long-lasting responses and cures in cancer patients. We investigated the long-term consequences of genetically impaired angiogenesis by engineering multiple tumor models deprived of endoglin, a co-receptor for TGF-beta in endothelial cells actively engaged in angiogenesis. Tumors from endoglin-deficient mice adapted to the weakened angiogenic response, and refractoriness to diminished endoglin signaling was accompanied by increased metastatic capability. Mechanistic studies in multiple mouse models of cancer revealed that deficiency for endoglin resulted in a tumor vasculature that displayed hallmarks of endothelial-to-mesenchymal transition, a process of previously unknown significance in cancer biology, but shown by us to be associated with a reduced capacity of the vasculature to avert tumor cell intra- and extravasation. Nevertheless, tumors deprived of endoglin exhibited a delayed onset of resistance to anti-VEGF (vascular endothelial growth factor) agents, illustrating the therapeutic utility of combinatorial targeting of multiple angiogenic pathways for the treatment of cancer.}}, author = {{Anderberg, Charlotte and Cunha, Sara I. and Zhai, Zhenhua and Cortez, Eliane and Pardali, Evangelia and Johnson, Jill R. and Franco, Marcela and Paez-Ribes, Marta and Cordiner, Ross and Fuxe, Jonas and Johansson, Bengt R. and Goumans, Marie-Jose and Casanovas, Oriol and ten Dijke, Peter and Arthur, Helen M. and Pietras, Kristian}}, issn = {{1540-9538}}, language = {{eng}}, number = {{3}}, pages = {{563--579}}, publisher = {{Rockefeller University Press}}, series = {{Journal of Experimental Medicine}}, title = {{Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination}}, url = {{https://lup.lub.lu.se/search/files/4195643/4022920.pdf}}, doi = {{10.1084/jem.20120662}}, volume = {{210}}, year = {{2013}}, }